{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:05:51Z","timestamp":1789146351609,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117213","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:18:42Z","timestamp":1785514722000},"page":"117213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vivo CRISPR screening identifies LTA4H as a target for potentiating immunotherapy efficacy via the LTB4-neutrophil axis"],"prefix":"10.1016","volume":"187","author":[{"given":"Guanwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haokai","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoyu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2026.117213_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117213_bb0015","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","article-title":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial","volume":"32","author":"Yap","year":"2026","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117213_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and Back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0025","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117213_bb0030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.117213_bb0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00262-024-03825-z","article-title":"Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors","volume":"73","author":"Malhotra","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0045","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117213_bb0050","article-title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117213_bb0055","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117213_bb0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.37349\/etat.2024.00212","article-title":"Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment","volume":"5","author":"Jou","year":"2024","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.intimp.2026.117213_bb0065","article-title":"Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."},{"issue":"9\u201310","key":"10.1016\/j.intimp.2026.117213_bb0070","first-page":"684","article-title":"Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance","volume":"40","author":"Wang","year":"2025","journal-title":"Genes Dev."},{"issue":"599","key":"10.1016\/j.intimp.2026.117213_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117213_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217913","article-title":"Hypoxia and immunometabolism in the tumor microenvironment: insights into mechanisms and therapeutic potential","volume":"631","author":"Wu","year":"2025","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.intimp.2026.117213_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.02.005","article-title":"Neutrophil profiling illuminates anti-tumor antigen-presenting potency","volume":"187","author":"Wu","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.117213_bb0095","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117213_bb0100","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.molcel.2021.08.027","article-title":"Lipid metabolism in sickness and in health: emerging regulators of lipotoxicity","volume":"81","author":"Yoon","year":"2021","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.intimp.2026.117213_bb0105","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat. Immunol."},{"issue":"39","key":"10.1016\/j.intimp.2026.117213_bb0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406325121","article-title":"In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer","volume":"121","author":"Feng","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0115","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1038\/s41467-025-63592-y","article-title":"In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target","volume":"16","author":"Fu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0120","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-023-40326-6","article-title":"A genetically encoded sensor for visualizing leukotriene B4 gradients in vivo","volume":"14","author":"Tam\u00e1s","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2026.117213_bb0125","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s11427-023-2444-5","article-title":"Targeting LTA4H facilitates the reshaping of the immune microenvironment mediated by CCL5 and sensitizes ovarian cancer to cisplatin","volume":"67","author":"Guo","year":"2024","journal-title":"Sci. China Life Sci."},{"issue":"9","key":"10.1016\/j.intimp.2026.117213_bb0130","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2024014947","article-title":"Neutrophil recruitment depends on platelet-derived leukotriene B4","volume":"9","author":"Hackenbroch","year":"2025","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.intimp.2026.117213_bb0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ccell.2023.01.002","article-title":"Neutrophil-activating therapy for the treatment of cancer","volume":"41","author":"Linde","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.117213_bb0140","article-title":"LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1\/LTBP1\/TGF-\u03b2 axis","volume":"6","author":"Yang","year":"2025","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.intimp.2026.117213_bb0145","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117213_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154968","article-title":"Blocking LTB4 signaling-mediated TAMs recruitment by Rhizoma Coptidis sensitizes lung cancer to immunotherapy","volume":"119","author":"Yan","year":"2023","journal-title":"Phytomedicine"},{"issue":"9","key":"10.1016\/j.intimp.2026.117213_bb0155","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2024014947","article-title":"Neutrophil recruitment depends on platelet-derived leukotriene B4","volume":"9","author":"Hackenbroch","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12967-023-04804-1","article-title":"ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.117213_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073735","article-title":"The tumor microenvironment mediates the HIF-1\u03b1\/PD-L1 pathway to promote immune escape in colorectal cancer","volume":"25","author":"Sun","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117213_bb0170","article-title":"Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117213_bb0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41423-024-01130-4","article-title":"Activation of leukotriene B4 receptor 1 is a prerequisite for complement receptor 3-mediated antifungal responses of neutrophils","volume":"21","author":"Xin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0180","first-page":"vdae055","article-title":"Radiogenomic biomarkers for immunotherapy in glioblastoma: a systematic review of magnetic resonance imaging studies","volume":"6","author":"Ghimire","year":"2024","journal-title":"Neurooncol. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2026.117213_bb0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0022-3565(25)09503-5","article-title":"The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696","volume":"273","author":"Showell","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2026.117213_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.123887","article-title":"An enzyme activated fluorescent probe for LTA4H activity sensing and its application in cancer screening","volume":"253","author":"Wan","year":"2023","journal-title":"Talanta"},{"issue":"6","key":"10.1016\/j.intimp.2026.117213_bb0195","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcf.2021.08.007","article-title":"Empire-CF study: a phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis","volume":"20","author":"Elborn","year":"2021","journal-title":"J. Cyst. Fibros."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926010593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:53Z","timestamp":1789142813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926010593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S1567576926010593"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117213","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo CRISPR screening identifies LTA4H as a target for potentiating immunotherapy efficacy via the LTB4-neutrophil axis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117213"}}